Published in Semin Pediatr Neurol on June 01, 2006
RNA and disease. Cell (2009) 7.98
Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron (2011) 2.19
Determinants of the Usage of Splice-Associated cis-Motifs Predict the Distribution of Human Pathogenic SNPs. Mol Biol Evol (2015) 1.46
Structure of a key intermediate of the SMN complex reveals Gemin2's crucial function in snRNP assembly. Cell (2011) 1.29
A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev (2010) 1.27
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet (2008) 1.26
Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat (2013) 1.23
Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl Cell Differ (2009) 1.17
SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain. Hum Mol Genet (2008) 1.07
Inactivation of the SMN complex by oxidative stress. Mol Cell (2008) 1.06
SpliceDisease database: linking RNA splicing and disease. Nucleic Acids Res (2011) 1.05
High-efficiency transfection of cultured primary motor neurons to study protein localization, trafficking, and function. Mol Neurodegener (2010) 1.02
Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy. Cell Res (2012) 0.97
Dynamics of survival of motor neuron (SMN) protein interaction with the mRNA-binding protein IMP1 facilitates its trafficking into motor neuron axons. Dev Neurobiol (2013) 0.91
Molecular characterization of SMN copy number derived from carrier screening and from core families with SMA in a Chinese population. Eur J Hum Genet (2010) 0.91
Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice. PLoS One (2013) 0.90
mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacol (2012) 0.89
Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III. BMC Med Genet (2011) 0.88
Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophy. Hum Genet (2008) 0.86
The therapeutic potential of chemical chaperones in protein folding diseases. Prion (2014) 0.79
Failure of lower motor neuron radial outgrowth precedes retrograde degeneration in a feline model of spinal muscular atrophy. J Comp Neurol (2012) 0.79
Different Stability and Proteasome-Mediated Degradation Rate of SMN Protein Isoforms. PLoS One (2015) 0.77
Inhibition of histone deacetylase (HDAC) by 4-phenylbutyrate results in increased junctional conductance between rat corpora smooth muscle cells. Front Pharmacol (2015) 0.77
High expression level of Tra2-β1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice. PLoS One (2015) 0.77
Investigations of curcumin and resveratrol on neurite outgrowth: perspectives on spinal muscular atrophy. Biomed Res Int (2014) 0.75
Phenyl acyl acids attenuate the unfolded protein response in tunicamycin-treated neuroblastoma cells. PLoS One (2013) 0.75
Genetic findings of Cypriot spinal muscular atrophy patients. Neurol Sci (2015) 0.75
MotomiRs: miRNAs in Motor Neuron Function and Disease. Front Mol Neurosci (2017) 0.75
SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet (2010) 1.80
Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med (2008) 1.66
In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem (2006) 1.48
Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol (2005) 1.39
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem (2005) 1.35
The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet (2006) 1.27
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet (2008) 1.26
An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival. Genome Res (2006) 1.25
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet (2009) 1.21
Histone deacetylase inhibitors increase neuronal differentiation in adult forebrain precursor cells. Exp Brain Res (2007) 1.19
Deep sequencing reveals increased DNA methylation in chronic rat epilepsy. Acta Neuropathol (2013) 1.18
Increased reelin promoter methylation is associated with granule cell dispersion in human temporal lobe epilepsy. J Neuropathol Exp Neurol (2009) 1.07
Low proliferation and differentiation capacities of adult hippocampal stem cells correlate with memory dysfunction in humans. Brain (2010) 1.07
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther (2006) 1.06
Cellular characterization of the peritumoral edema zone in malignant brain tumors. Cancer Sci (2009) 1.04
Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet (2010) 1.03
Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. Technical note. J Neurosurg (2005) 1.03
Pronounced conformational changes following agonist activation of the M(3) muscarinic acetylcholine receptor. J Biol Chem (2005) 1.01
The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther (2007) 0.99
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res (2014) 0.99
Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction. PLoS One (2012) 0.98
Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord (2010) 0.96
Spinal muscular atrophy and therapeutic prospects. Prog Mol Subcell Biol (2006) 0.95
Spontaneous in vitro transformation of adult neural precursors into stem-like cancer cells. Brain Pathol (2008) 0.94
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst (2015) 0.90
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Res (2013) 0.90
Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol (2006) 0.83
Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas. Acta Neuropathol (2006) 0.82
A novel large in-frame deletion within the CACNA1F gene associates with a cone-rod dystrophy 3-like phenotype. PLoS One (2013) 0.80
The x(c)(-) cystine/glutamate antiporter (xCT) as a potential target for therapy of cancer: yet another cytotoxic anticancer approach? J Cell Physiol (2009) 0.80
PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion. PPAR Res (2008) 0.79
RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. Breast Cancer Res (2013) 0.78
Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors. PPAR Res (2008) 0.75
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst (2017) 0.75
The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer. Eur J Cancer Prev (2017) 0.75